Eisai Deepens Its Oncology Evidence Base at ESMO Congress 2026Findings from the Phase 3 LITESPARK-011 and LITESPARK-012 studies reflect continued research into LENVIMA® (lenvatinib)-based combination regimens for patients with advanced renal cell carcinoma
Exploratory biomarker analysis from the Phase 3 LEAP-001 study adds to translational insights in advanced or recurrent endometrial cancer, alongside new findings from “Patients Raise Their Voices” survey

Our news releases are intended to disclose corporate information and are not intended for the promotion or advertising of prescription pharmaceuticals or investigational products, nor are they intended to provide medical advice.
Please note that the information contained in news releases is current as of the date of publication.